pharm - onc Flashcards
vinca alkaloids and taxols effect what part of the cell cycle
M
antmetabolites effect what part of the cell cycle
S (DNA sythesis)
etoposide effects effect what part of the cell cycle
S (DNA synth) and G2 (synthesis of compenents needed for Mitosis)b
bleomycin effect what part of the cell cycle
G2 (synthesis of compenents needed for Mitosis)
drugs effecting thymidine synth
MTX, 5-FU,
drugs effecting purine synth
6-MP
drugs effecting DNA cross-linking
alkalyating agents, cisplatin
drugs that intercalate DNA
dactomycin, doxurubin
drugs that inhibit topoisomerase
etoposide
drugs that inhibit microtubule formatino
vinca alkaloids
drugs that inhibt microtubule dissaebmly
paclitaxel
MOA of MTX
folic acid analog - inhibts dihydrofolate reductace –>
effect of MTX
inhibits DNA and protein synth
use of MTX
blood cancers, choricocarcinomas
non cancer use of MTX
abortion, ectopic, RA, psoriasis
tox of MTX
myeosuppression, fatty liver, mucositis, birth defects
“rescue” of MTX
leucovorin
5-FU MOA
pyramidine analog converted to 5f-dUMP - complexes folic acid
effect of 5-FU
inhibits DNA and protein synth
use of 5-FU
colon cancer, basal cell carcinoma
tox of 5-FU
myleosuppression , photosensitivity
rescue of 5-FU
thymidine
MOA of cytarabine
pyramdine analog, inhibits DNA polymerase
use of cytarabine
blood cancers
tox of cytarabine
leukopenia, thrombocytopenia, megaloblastic anemia
6-MO/6-TG/azathrioprine MOA
purine anologs –> inhibit de novo purine synth
use of 6-MO/6-TG/azathrioprine
leukemia
6-MO/6-TG/azathrioprine tox
bone marrow, GI and liver tox
reacts with allopurinol
dactinomycin MOA
intercalates in DNA
use of dactinomycin
kids tumors
Tox od dactinomycin
myleosupression
doxirubicin MOA
generates free radicals, breaks DNA
use of doxirubicin
solid tumors, blood cancers
SE of doxirubicin
dilatated cardiomyopathy
myleosuppression
alopecia
can be toxic to exposed tissues
used to chelate doxirubicin from heart
dexrazoxane
bleolycin MOA
induces free radicals
Bleomycin use
testicular cancer, hodgkin’s lymphoma
bleomycin tox
pulmonanry fibrosis
skin changes
some myleosuppression
cylcophosphamide MOA
interstrands DNA at guinine (must be activated by liver)
use of cylcophosphamide
brain tumors
SE of cylcophosphamide
CNS tox
busulfan MOA
alklylates DNA
busulfan use
CML (and ablates pts marrow before transplantation)
Busulfan tox
pulmonary fibrosis
vincristine/vinblastine MOA
bind to tubulin in M phase and blowck microtubules. mitoic spindle cannot form
use of vincristine/vinblastine
solid tumors, blood cancer
tox of vincristine
neurotox (areflexia,pripheral neutitis, paralytic ileus)
tx of vinblastine
severe bone marrow suppression
MOA of taxols
hyperstabalizes microtubules so the mitotic spindle cannot break down –> no anaphase
use of taxols
ovarian and breast carcinoma
tox of taxols
myleosuppression and hypersensitivity
MOA of cisplatin/carboplatin
cross-links DNA
use of cisplatin/carboplatin
testicular, bladder,ovary, and lung carcinomas
tox of cisplatin/carboplatin
nephro.ototox
prevent nephrotix in cisplatin/carboplatin with
amifostine ad chloride diuresis
etoposide, teniposide MOA
inhibit topiisomerase II
use of etoposide, teniposide
solid tumors, blood cancers
tox of etoposide, teniposide
myleosuppression, GI irritation, alopecia
hydroxyurea MOA
inhibits ribonucleotide reductase –> inhibits S phase DNA synthesis
use of hydroxyurea
melanoma, CML, sickle cell
tox of hydroxyurea
bone marrow suppression, GI upset
cancer use of predisone
CLL, non-HL,
tamoxifen MOA
SERM. Blocks estrogen binding in estrogen receptor + cells
use of tamoxifen
breast cancer tx and prevention - also prevents osteoporosis
tox of tamoxfen
can increase risk of endometrial cancer
SERM that does in increase risk of endometrial cancer
raloxafine
trastuzumab MOA
monoclonal antobody against HER-2
use of trastuzumab
MER-2 + breast cancer
tox of trastuzumab
cardiotox
imatinb (Gleevec) MOA
philly chromosome TK inhibitor
use of imatinb (Gleevec)
CML, GI stromal tumors
tox of imatinb (Gleevec)
fluid retention
rituximab MOA
monoclonal antobody against CD-20 on B cells
use of rituximab
NHL, RA (with MTX)
vemurafenib MOA
inhibis B-Raf kinase with v600E mutation
vemurafenib use
metastatic melanoma
bevacizumab MOA
monoclonal antibody against VEGF (inhibts angiogenesis)
bevacizumab use
solid tumors